

# HEALTH SCIENCES AUTHORITY

## REGULATORY GUIDANCE

**JANUARY 2026**

# **TRADITIONAL MEDICINES GUIDELINES**

**GL-CHPB-4-003 Rev. No. 003**

The information in these Guidelines may be updated from time-to-time. For the latest version of the Guidelines, please refer to our website at [www.hsa.gov.sg](http://www.hsa.gov.sg).



| <b><u>Content:</u></b>                                                | <b><u>Page</u></b> |
|-----------------------------------------------------------------------|--------------------|
| 1. <a href="#">Introduction</a>                                       | 3                  |
| 2. <a href="#">Legislation</a>                                        | 3                  |
| 3. <a href="#">Working Definition</a>                                 | 3                  |
| 4. <a href="#">Safety and Quality Standards</a>                       | 4                  |
| 5. <a href="#">Product Label Information</a>                          | 6                  |
| 6. <a href="#">Traditional Medicines Claims</a>                       | 6                  |
| 7. <a href="#">Medical Advertisements and Sales Promotion Control</a> | 7                  |
| 8. <a href="#">Product and Dealer Licensing Control</a>               | 7                  |

## 1. Introduction

- 1.1 These guidelines provide regulatory information for companies dealing with Traditional Medicines (TM) in Singapore. The information provided in these guidelines is not meant to supersede or replace any of the legislation. Other national legislative controls may apply where applicable.

## 2. Legislation

- 2.1 The current legislative control that may apply to TM may be found in the following legislation:
- a. Medicines Act 1975 & its Subsidiary Legislation especially:
    - i. Medicines (Prohibition of Sale, Supply and Importation) Order;
    - ii. Medicines (Traditional Medicines, Homoeopathic Medicines and Other Substances) (Exemption) Order;
    - iii. Medicines (Labelling) Regulations;
    - iv. Medicines (Medical Advertisements) Regulations;
    - v. Medicines (Licensing, Standard Provisions & Fees) Regulations
  - b. Medicines (Advertisement & Sale) Act 1955
  - c. Poisons Act 1938 & Poisons Rules

## 3. Working Definition

- 3.1 A working definition of TM is described below:

In the local context, TM refer to Malay and Indian traditional medicinal products. They are finished products containing ingredients with uses documented in relevant TM references.

TM are presented in dosage forms to be administered in small unit doses such as capsules, softgels, tablets, powders, and liquids. Forms which may be perceived as food or confectionery, such as sweet, chewable outer shell with semi-solid or liquid core would not be appropriate as TM dosage forms.

- 3.2 TM shall not include any of the following:
- a. Any product as a sole item of a meal or diet;
  - b. Any product that is defined otherwise in the legislation; and
  - c. Any preparation required to be sterile such as injections and eye drops.
- 3.3 Notwithstanding the above, the HSA reserves the right in determining the final product classification.

## 4. Safety and Quality Standards

4.1 Dealers (importers, manufacturers, wholesale dealers) and sellers have the obligation to ensure that their products are not harmful or unsafe, and that they conform with the applicable safety and quality standards.

4.2 Dealers are to ensure that TM do not contain any prohibited substances. Dealers must also ensure that products containing restricted ingredients are used with specific restrictions or conditions such as maximum daily dose limits or labelling specifications found in the [Guidelines on Prohibited and Restricted Ingredients in Health Supplements and Traditional Medicines](#).

4.3 Dealers are advised to hold evidence to support the safety of the ingredients used. The Guidelines for Establishing the Safety of Ingredients of Health Supplements and Traditional Medicines are available [here](#).

4.4 TM must not exceed the following heavy metals, microbial, diethylene glycol and ethylene glycol limits as specified in **Tables 1, 2, 3 and 4**.

**Table 1: Heavy Metals Limits**

| Heavy Metal | Quantity (by weight)  |
|-------------|-----------------------|
| Arsenic     | 5 parts per million   |
| Cadmium     | 0.3 parts per million |
| Lead        | 10 parts per million  |
| Mercury     | 0.5 parts per million |

**Table 2: Microbial Limits**

| Microbe                                                                         | Quantity (colony-forming units (CFU)) per g or ml of product |
|---------------------------------------------------------------------------------|--------------------------------------------------------------|
| Total aerobic microbial count:                                                  | Not more than $10^5$                                         |
| Yeast and mould count:                                                          | Not more than $5 \times 10^2$                                |
| <i>Escherichia coli</i> , <i>Salmonellae</i> and <i>Staphylococcus aureus</i> : | Absent                                                       |

**Table 3: Microbial Limits for Topical Use Products**

| Microbe                                                          | Quantity (colony-forming units (CFU)) per g or ml of product |
|------------------------------------------------------------------|--------------------------------------------------------------|
| Total aerobic microbial count:                                   | Not more than $10^4$                                         |
| Yeast and mould count:                                           | Not more than $5 \times 10^2$                                |
| <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> : | Absent                                                       |

**Table 4: Diethylene Glycol and Ethylene Glycol Limits**

| <b>Substance</b>  | <b>Quantity (by weight)</b> |
|-------------------|-----------------------------|
| Diethylene glycol | 1000 parts per million      |
| Ethylene glycol   | 1000 parts per million      |

The above limits for diethylene glycol and ethylene glycol are applicable to oral liquid preparations.

- 4.5 Dealers should perform routine testing on the finished products in accordance with HSA's Guidelines on Testing Requirements of Health Supplements and Traditional Medicines, to ensure that the products meet appropriate safety and quality standards. Dealers are to refer to the [Guidelines for Testing Requirements of Health Supplements and Traditional Medicines](#) for more information.
- 4.6 The physical test parameters for the different dosage forms of the finished products should also be monitored to ensure they consistently meet the required standards throughout the product life cycle. Dealers are to refer to the [Guidelines for Physical Test Parameters Based on Dosage Forms of Health Supplements and Traditional Medicines](#) for more information.
- 4.7 Dealers should ensure that the ingredient and finished product manufacturers comply with the manufacturing standards recommended in the [Guidelines for Manufacturing Standards of Health Supplements and Traditional Medicines](#), such as compliance with the principles of quality system, personnel, equipment, sanitation, hygiene, production, quality control, complaint handling, product recalls, and oversight of outsourced activities.
- 4.8 Dealers should hold product-related information and documents, including the following:
- Name of manufacturer and country of manufacture of each ingredient used in the product
  - Name of manufacturer and country of manufacture of the finished product
  - Certificate of analysis (including appropriate test parameters, their specifications and test method references) for each active ingredient used in the finished product
  - Product specification and certificate of analysis for every batch of finished product
  - Product distribution records
  - Records of reported adverse events, product defects, and product recalls

## 5. Product Label Information

- 5.1 The product label should be prominently displayed on the product. The information on the product label should be adequate and truthful to enable consumers to make informed decisions and use the product correctly. Dealers are to refer to the [Guidelines for Labelling Standards of Health Supplements and Traditional Medicines](#) for more information.

## 6. Traditional Medicines Claims

- 6.1 A claim refers to any message or representation made on a product in relation to its indications, benefits or action. Claims may be stated directly or inferred indirectly through, but not limited to, the following:
- Product label
  - Advertisements
  - Point of sales materials
  - Product brochures
- 6.2 In general, the claims made must be consistent with the definition of TM. The claims made should be:
- Limited to supporting and enhancing health
  - For managing or symptomatic relief of non-serious medical conditions, e.g. cough, cold, diarrhoea; and
  - Not directly or indirectly referring to the prevention, alleviation, treatment or cure of any of the 19 diseases or conditions specified in the First Schedule of Medicines Act
- 6.4 Claims for TM must be in line with the respective TM principles (such as Jamu, Ayurvedic Medicine) and supported by adequate evidence from TM-based references.
- 6.5 Dealers are to refer to the Guidelines for Claims and Claims Substantiation of Health Supplements and Traditional Medicines for more information including the general claim principles available [here](#).

## **7. Medical Advertisements and Sales Promotion Control**

- 7.1 TM are subject to medical advertisements and sales promotion permit control. A valid advertisement and sales promotion permit is required before publishing any medical advertisements or conducting any sales promotion activities directed to the general public.
- 7.2 Dealers are to refer to the advertisements and promotion guidelines for more information on what is required before you run any advertisements and promotions for your products.

## **8. Product and Dealer Licensing Control**

- 8.1 Currently, TM are not subject to premarket approval and licensing by HSA for their importation, manufacture and sales in Singapore.
- 8.2 Dealers (importers, manufacturers, wholesale dealers) and sellers have the obligation to ensure that their products are not harmful or unsafe, and that they conform with the applicable quality standards.

## References

1. ASEAN Guiding Principles for Inclusion into or Exclusion from the Negative List of Substances for Traditional Medicines

**Revision History**

| Version | Date of publication | Summary of changes*                                                                                                       |
|---------|---------------------|---------------------------------------------------------------------------------------------------------------------------|
| 1       | March 2022          | New document                                                                                                              |
| 2       | November 2024       | Added diethylene glycol and ethylene glycol limits                                                                        |
| 3       | January 2026        | Included reference to Guidelines on Prohibited and Restricted Ingredients in Health Supplements and Traditional Medicines |

\*Editorial changes are not reflected

# HEALTH SCIENCES AUTHORITY

Health Products Regulation Group  
Blood Services Group  
Applied Sciences Group

[www.hsa.gov.sg](http://www.hsa.gov.sg)

## Contact information

Complementary Health Products Branch  
Medicinal Products Pre-Market Cluster  
Health Products Regulation Group  
Health Sciences Authority

11 Biopolis Way  
Singapore 138667  
[www.hsa.gov.sg](http://www.hsa.gov.sg)  
Email: [hsa\\_chp@hsa.gov.sg](mailto:hsa_chp@hsa.gov.sg)

